Using metabolic syndrome traits for efficient detection of impaired glucose tolerance

Diabetes Care

Volumn 27, Issue 6, 2004, Pages 1417-1426

  Meigs, James B ^a,b   Williams, Ken ^c   Sullivan, Lisa M ^d   Hunt, Kelly J ^c   Haffner, Steven M ^c   Stern, Michael P ^c   González Villalpando, Clicerio ^e   Perhanidis, Jessica S ^a   Nathan, David M ^b   D'Agostino, Ralph B ^d,f   Wilson, Peter W F ^g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d BOSTON UNIVERSITY   (United States)

^e Centro de Estudios en Diabetes Mexico City   (Mexico)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL EXAMINATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; QUALITY OF LIFE; QUANTITATIVE TRAIT; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT;

EID: 2542503919     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.6.1417     Document Type: Article

References (45)

1. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, Thompson TJ: Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 24:1936-1940, 2001
2. Hogan P, Dall T, Nikolov P: Economic costs of diabetes in the U.S. in 2002. Diabetes Care 26:917-932, 2003
3. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
4. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
6. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
7. Benjamin SM, Valdez R, Geiss LS, Rolka DB, Narayan KM: Estimated number of adults with pre-diabetes in the U.S. in 2000: opportunities for prevention. Diabetes Care 26:645-649, 2003
8. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553, 1998
9. Charles MA, Fontbonne A, Thibult N, Warnet JM, Rosselin GE, Eschwege E: Risk factors for NIDDM in white population: Paris prospective study. Diabetes 40: 796-799, 1991
10. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoom Study. JAMA 285:2109-2113, 2001]
11. Vaccaro O, Ruffa G, Imperatore G, Iovino V, Rivellese AA, Riccardi G: Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. Diabetes Care 22:1490-1493, 1999
12. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, Knowler WC: The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23:1108-1112, 2000
13. DECODE Study Group: Consequences of the new diagnostic criteria for diabetes in older men and women: DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). Diabetes Care 22:1667-1671, 1999
14. Shaw JE, de Courten M, Boyko EJ, Zimmet PZ: Impact of new diagnostic criteria for diabetes on different populations. Diabetes Care 22:762-766, 1999
15. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes 20:1183-1197, 1997
16. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
17. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of diabetes? JAMA 263:2893-2898, 1990
18. Stern MP, Williams K, Haffner SM: Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136: 575-581, 2002
19. Kannel WB, Feinleib M, McNamara JR, Garrison RJ, Castelli WP: An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol 110:281-290, 1979
20. Meigs JB, Nathan DM, Wilson PWF, Cupples LA, Singer DE: Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham Offspring Study. Ann Intern Med 128:524-533, 1998
21. McNamara JR, Schaefer EJ: Automated enzymatic standardized lipid analyses for plasma and lipid lipoprotein fractions. Clin Chim Acta 166:1-8, 1987
22. Warnick GR, Benderson J, Albers JJ: Dextran sulfate-magnesium precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem 28: 1379-1382, 1982
23. Stern MP, Rosenthal M, Haffner SM, Hazuda HP, Franco LJ: Sex differences in the effect of sociocultural status on diabetes and cardiovascular risk factors in Mexican-Americans: the San Antonio Heart Study. Am J Epidemiol 120:834-851, 1984
24. Stern MP, Patterson JK, Haffner SM, Hazuda HP, Mitchell BD: Lack of awareness and treatment of hyperlipidemia in type II diabetes in a community survey. JAMA 262:360-364, 1989
25. Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM, Stern MP: Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med 159: 1450-1456, 1999
26. Haffner SM, Gonzalez C, Mykkanen L, Stern M: Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion to NIDDM: the Mexico City Diabetes Study. Diabetologia 40:830-837, 1997
27. Burke JP, Williams K, Haffner SM, Villalpando CG, Stern MP: Elevated incidence of type 2 diabetes in San Antonio, Texas, compared with that of Mexico City, Mexico. Diabetes Care 24:1573-1578, 2001
28. Wagenknecht LE, Mayer EJ, Rewers M, Haffner S, Selby J, Borok GM, Henkin L, Howard G, Savage PJ, Saad MF, et al.: The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Ann Epidemiol 5:464-472, 1995
29. Haffner SM, D'Agostino R, Saad MF, Rewers M, Mykkanen L, SelbyJ, Howard G, Savage PJ, Hamman RF, Wagenknecht LE, Bergman RN: Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Diabetes 45:742-748, 1996
30. National Cholesterol Education Program: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
31. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167, 2003
32. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P: Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286:180-187, 2001
33. Meigs JB, Wilson PWF, Nathan DM, D'Agostino RB, Williams K, Haffner SM: Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 52:2160-2167, 2003
34. National Institutes of Health: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 6 (Suppl. 2): 51S-209S, 1998
35. Meigs JB: The metabolic syndrome. BMJ 327:61-62, 2003
36. DECODE Study Group: Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes: reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. BMJ 317:371-375, 1998
37. Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R: The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes 52:1475-1484, 2003
38. Carnevale Schianca GP, Rossi A, Sainaghi PP, Maduli E, Bartoli E: The significance of impaired fasting glucose versus impaired glucose tolerance: importance of insulin secretion and resistance. Diabetes Care 26:1333-1337, 2003
39. Saydah SH, Byrd-Holt D, Harris MI: Projected impact of implementing the results of the diabetes prevention program in the U.S. population. Diabetes Care 25:1940-1945, 2002
40. Anand SS, Razak F, Vuksan V, Gerstein HC, Malmberg K, Yi Q, Teo KK, Yusuf S: Diagnostic strategies to detect glucose intolerance in a multiethnic population. Diabetes Care 26:290-296, 2003
41. Lindahl B, Weinehall L, Asplund K, Hallmans G: Screening for impaired glucose tolerance: results from a population-based study in 21,057 individuals. Diabetes Care 22:1988-1992, 1999
42. Nelson KM, Boyko EJ: Predicting impaired glucose tolerance using common clinical information: data from the Third National Health and Nutrition Examination Survey. Diabetes Care 26:2058-2062, 2003
43. Schmidt MI, Duncan BB, Vigo A, Pankow J, Ballantyne CM, Couper D, Brancati F, Folsom AR: Detection of undiagnosed diabetes and other hyperglycemia states: the Atherosclerosis Risk in Communities Study. Diabetes Care 26:1338-1343, 2003
44. Burke JP, Williams K, Narayan KM, Leibson C, Haffner SM, Stern MP: A population perspective on diabetes prevention: whom should we target for preventing weight gain? Diabetes Care 26:1999-2004, 2003
45. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JP, Sjostrom L: Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 160:1321-1326, 2000